Evidence map›Paper›PMID 35226500›Full record

ArticleMolecular pharmaceutics2022

Structural Characterization Study of a Lipid Nanocapsule Formulation Intended for Drug Delivery Applications Using Small-Angle Scattering Techniques.

Dileep Urimi, Maja Hellsing, Najet Mahmoudi, Christopher Söderberg, Ronja Widenbring, Lars Gedda, Katarina Edwards, Thorsteinn Loftsson, Nicolaas Schipper

Open access · hybridAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. High-Throughput Strategies for Streamlining Lipid Nanoparticle Development Pipeline.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.Small (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  13. Article
  14. Drug Product Development of Lipid Nanoparticle-Based mRNA Therapeutics and Vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Dileep UrimiRISE Research Institutes of Sweden, Division Bioeconomy and Health, Chemical Process and Pharmaceutical Development, Forskargatan 18, Södertälje 151 36, Sweden.ORCID 0000-0002-1463-4990
Maja HellsingRISE Research Institutes of Sweden, Division Bioeconomy and Health, Chemical Process and Pharmaceutical Development, Forskargatan 18, Södertälje 151 36, Sweden.
Najet MahmoudiISIS Pulsed Neutron and Muon Source, Rutherford Appleton Laboratory, Didcot OX11 0QX, U.K.
Christopher SöderbergRISE Research Institutes of Sweden, Division Bioeconomy and Health, Chemical Process and Pharmaceutical Development, Forskargatan 18, Södertälje 151 36, Sweden.
Ronja WidenbringRISE Research Institutes of Sweden, Division Bioeconomy and Health, Chemical Process and Pharmaceutical Development, Forskargatan 18, Södertälje 151 36, Sweden.
Lars GeddaDepartment of Chemistry - Ångström laboratory, Uppsala University, Box 573, Uppsala SE-751 23, Sweden.
Katarina EdwardsDepartment of Chemistry - Ångström laboratory, Uppsala University, Box 573, Uppsala SE-751 23, Sweden.
Thorsteinn LoftssonFaculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Hofsvallagata 53, Reykjavík IS-107, Iceland.ORCID 0000-0002-9439-1553
Nicolaas SchipperRISE Research Institutes of Sweden, Division Bioeconomy and Health, Chemical Process and Pharmaceutical Development, Forskargatan 18, Södertälje 151 36, Sweden.
RISE Research Institutes of Sweden · SEUniversity of Iceland · ISUppsala University · SERutherford Appleton Laboratory · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid nanocapsules (LNCs) are increasingly being used for various drug delivery applications due to their versatile nature and ability to carry a wide variety of therapeutic drug molecules. In the present investigation, small-angle X-ray (SAXS) and neutron scattering (SANS) techniques were used to elucidate the structure of LNCs. Overall, size measurements obtained from SAXS and SANS techniques were complemented with dynamic light scattering, zeta potential, and cryogenic transmission electron microscopy measurements. The structural aspects of LNCs can be affected by drug loading and the properties of the drug. Here, the impact of drug loading on the overall structure was evaluated using DF003 as a model drug molecule. LNCs with varying compositions were prepared using a phase inversion method. Combined analysis of SAXS and SANS measurements indicated the presence of a core-shell structure in the LNCs. Further, the drug loading did not alter the overall core-shell structure of the LNCs. SANS data revealed that the core size remained unchanged with a radius of 20.0 ± 0.9 nm for unloaded LNCs and 20.2 ± 0.6 nm for drug-loaded LNCs. Furthermore, interestingly, the shell becomes thicker in an order of ∼1 nm in presence of the drug compared to the shell thickness of unloaded LNCs as demonstrated by SAXS data. This can be correlated with the strong association of hydrophilic DF003 with Kolliphor HS 15, a polyethylene glycol-based surfactant that predominantly makes up the shell, resulting in a drug-rich hydrated shell.

Indexed as

NanocapsulesLipidsParticle SizeScattering, Small AngleX-Ray DiffractionLipidsNanocapsulescore−shell structureDF003lipid nanocapsulesLNCnanoparticlesSANSSAXSsmall-angle neutron scatteringsmall-angle X-ray scattering

Identifiers

PMID35226500
PMCPMC8985204
OpenAlexW4214621037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.